Notably, genetic polymorphism of TM6SF2 in the dominant model was independently linked to the risk of developing NAFLD, and PNPLA3 genetic variants additively increased vulnerability to NAFLD‐related hepatic fibrosis. Here, PNPLA3 is linked to metabolic dysfunction-associated steatotic liver disease.